A Randomized Phase II Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Resected Stages IIB/C, III, and IV Melanoma
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Melanoma vaccine (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 21 May 2014 Biomarkers information updated
- 18 Jan 2008 Status change from recruiting to terminated, from clinicaltrials.gov record.
- 04 Dec 2005 New trial record.